EMA
- Application: EMEA/H/C/006475
- Local brand name: Blarcamesine Anavex
- Indication: Treatment of Alzheimer’s disease and dementia.
- Status: withdrawn
ANAVEX2-73 oral liquid (ANAVEX2-73 oral liquid) regulatory status in European Union.
Yes. EMA has authorised it.
Anavex Life Sciences Corp. is the originator. The local marketing authorisation holder may differ — check the official source linked above.